Document is current
Any future updates will be listed below
-
Authors
Larsen, Anders Hostrup https://orcid.org/0000-0003-1127-6910
Wiggers, Henrik
Dollerup, Ole Lindgård
Jespersen, Nichlas Riise
Hansson, Nils Henrik
Frøkiær, Jørgen
Brøsen, Kim
Nørrelund, Helene
Bøtker, Hans Erik
Møller, Niels
Jessen, Niels https://orcid.org/0000-0001-5613-7274
-
Funding
Funding for this research was provided by:
Danish Diabetes Academy supported by the Novo Nordisk Foundation (OL8201)
Det Frie Forskningsråd (4183-00384)
Novo Nordisk Fonden (NNF13OC0003882)
Arvid Nilssons Fond (Dok 1780631)
Sundhedsvidenskabelige Fakultet, Aarhus Universitet (phd0115)
Hjerteforeningen (15-R99-A5947-22932; 15-R99-A5947-22933)
Kirsten Anthonius Mindefond (N/A)
Health Research Fund of Central Denmark Region (N/A)
Augustinus Fonden (15-4919)
Aase og Ejnar Danielsens Fond (10-001657)
Helga og Peter Kornings Fond (55027-100)
Familien Hede Nielsens Fond (N/A)
- License Information
-
More Information
Article History
Accepted: 1 August 2020
First Online: 8 August 2020
Compliance with Ethical Standards
:
: Merck KGaA (Darmstadt, Germany) provided the metformin (Glucophage XR®) and placebo tablets free of charge. Merck KGaA reviewed the manuscript for medical accuracy only before journal submission. The authors are fully responsible for the content of this manuscript, and the views and opinions described in the publication reflect solely those of the authors. H.W. has been the principal or a sub-investigator in studies involving the following pharmaceutical companies: MSD, Bayer, Daiichi-Sankyo, Novartis, Novo Nordisk, Sanofi-Aventis, and Pfizer. The other authors report no conflicts.
